Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor

Nisha S Joseph,1 Yu-Tzu Tai,2 Kenneth C Anderson,2 Sagar Lonial1 1Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; 2Dana-Farber Cancer Institute, Harvard University, Boston, MA, USACorrespondence: Kenneth C AndersonDana-Farber Cancer Institute, Blood Compont, D289, 44...

Full description

Bibliographic Details
Main Authors: Joseph NS, Tai YT, Anderson KC, Lonial S
Format: Article
Language:English
Published: Dove Medical Press 2021-08-01
Series:Clinical Pharmacology : Advances and Applications
Subjects:
belantamab mafodotin
belamaf
selinexor
relapsed/refractory myeloma
myeloma
Online Access:https://www.dovepress.com/novel-approaches-to-treating-relapsed-and-refractory-multiple-myeloma--peer-reviewed-fulltext-article-CPAA

Internet

https://www.dovepress.com/novel-approaches-to-treating-relapsed-and-refractory-multiple-myeloma--peer-reviewed-fulltext-article-CPAA

Similar Items